Monte Rosa Therapeutics, Inc.

NASDAQ:GLUE

Biotechnology

Healthcare
$9.07 -1.39%

-$0.26 today

Market cap
$775.03M
Beta
1.60
P/E (TTM)
-9.1
EPS (TTM)
-$1.98
52W Low $4.12High $25.77

Volume 1.26M

Average 1.02M

GLUE Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Monte Rosa Therapeutics, Inc.NASDAQ: GLUE

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 51.8%

Gross margin was 51.8% in Q1 FY2026, down 48.2 pp from a year earlier. On a trailing-twelve-month basis it was 95.3%, down 3.4 pp year over year.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
51.8%-48.2 pp QoQ
Last fiscal yearDec 2025
93.2%+4.0 pp YoY
LTMMar 2026
95.3%-3.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-48.2 pp——
1 year+4.0 pp——
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
93.2%
Year-over-year change
+4.0pp

Gross Margin vs competitors

How GLUE compares with its peers on the latest reported figures

  • GLUE's LTM Mar 2026 gross margin of 95.3% is the 2nd highest of the 4 companies compared; the peer median is 94.8%.
  • Its year-over-year change of -3.4 pp is the lowest of 4, against a peer median of +9.6 pp.
GLUE Competitors Peer median
Gross Margin for GLUE and competitors
Company Period LTM level YoY 3-year change
ARVNArvinas, Inc.LTM Mar 202697.4% -2.2 pp-2.0 pp
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 202695.3% -3.4 pp—
CCCCC4 Therapeutics, Inc.LTM Mar 202694.8% +9.6 pp-22.2 pp
NRIXNurix Therapeutics, Inc.LTM Aug 202686.5% +249.4 pp+455.2 pp
Peer median (excluding GLUE) 94.8%+9.6 pp-2.0 pp

Competitors are the stored peer set for GLUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00075.62M123.67M
Cost of Revenue006.22M8.12M8.36M
Gross Profit00(6.22M)67.5M115.32M
Gross Margin———89.3%93.2%
Research & Development57.16M85.06M105.05M121.56M141.5M
Selling, General & Admin15.73M27.32M32.04M35.17M36.38M
Operating Expenses72.88M112.38M137.09M148.61M169.52M
Depreciation & Amortization2.13M3.75M6.22M8.12M8.36M
EBITDA(71.83M)(100.99M)(128.79M)(62.01M)(31.37M)
EBITDA Margin———-82.0%-25.4%
Operating Income(72.88M)(112.38M)(143.31M)(81.11M)(54.21M)
Operating Margin———-107.3%-43.8%
Interest Income46K3.76M9.33M10.57M12.94M
Interest Expense03.76M000
Other Income / Expenses(1.08M)3.88M8.3M10.98M14.49M
Income Before Tax(73.96M)(108.5M)(135.01M)(70.13M)(39.72M)
Pre-Tax Margin———-92.7%-32.1%
Income Tax Expense00338K2.57M(1.1M)
Net Income(73.96M)(108.5M)(135.35M)(72.7M)(38.63M)
Net Margin———-96.1%-31.2%
EPS (Basic)(1.59)(2.30)(2.63)(0.98)(0.46)
EPS (Diluted)(1.59)(2.30)(2.63)(0.98)(0.46)
Weighted Avg Shares46.54M47.23M51.4M73.91M83.07M
Weighted Avg Shares (Diluted)46.54M47.23M51.4M73.91M83.07M

Monte Rosa Therapeutics, Inc.

NASDAQ:GLUE

Intrinsic Alpha fair value

Locked

Current Price

$9.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.